For decades, clinicians approached dry eye disease by sorting patients into two broad categories, a framework that increasingly strained under the weight of clinical reality. In 2025, the Tear Film & Ocular Surface Society released TFOS DEWS III, a landmark update that asks practitioners to set aside rigid classification in favour of understanding the unique constellation of drivers behind each patient's condition. The shift reflects a deeper truth about chronic disease: that the human body rarely conforms to the boxes we build for it, and that lasting care begins with careful, individualised
TFOS DEWS III: New Framework Shifts Dry Eye Diagnosis to Driver-Based Approach
Related Coverage
Sony introduced the FE 8-14mm F3.5 Fisheye G, its first standalone fisheye lens for full-frame E-mount cameras, offering…
BBC News · Sep 09 Tung Chee-hwa, Hong Kong's First Post-Handover Leader, Dies at 89Tung Chee-hwa, Hong Kong's first leader after the 1997 British handover, has died at 89. His tenure was marked by financ…
The Guardian · Sep 09 Maternal anaemia linked to smaller brains in infants, study warnsA study of over 300 mothers in Cape Town found babies born to anaemic mothers have 4% smaller brains, particularly in re…
Associated Press · Sep 09 SEC leaders weigh LSU expulsion over pro player roster violationsSEC leaders are discussing expelling LSU after the university attempted to roster professional players, violating NCAA r…
Bias & Framing
Medical education article presenting TFOS DEWS III framework with minimal bias; authored by credentialed academics and focused on clinical guidance without apparent advocacy.
Educational/instructional framing presenting clinical guidelines as evidence-based updates; uses authoritative expert voices to establish credibility and legitimacy of new diagnostic approach.
Geopolitical Impact
Medical framework update on dry eye disease diagnosis has no geopolitical implications; this is a clinical guideline for healthcare professionals.
Economic Lens
New clinical framework for dry eye disease diagnosis shifts from rigid classification to driver-based approach, potentially expanding treatment markets and improving patient outcomes through personalized care strategies.
Patients may experience improved diagnostic accuracy and more targeted, personalized treatment plans, potentially reducing trial-and-error approaches and improving quality of life for dry eye sufferers. However, implementation costs may initially increase healthcare expenses.
Healthcare regulators and professional bodies may need to update reimbursement frameworks to reflect new diagnostic protocols. Training requirements for eyecare professionals may increase. Potential for standardized guidelines to reduce diagnostic variability across practitioners.